Ifosfamide – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 104 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

On this page12 sections

Article Summary

Ifosfamide is a parenterally administered alkylating agent similar to cyclophosphamide that is used in the treatment of several forms of cancer including lymphomas, sarcoma, and advanced forms of solid organ cancer such as breast, testicular, ovarian, gastric, and lung cancer. Ifosfamide therapy is associated with minor transient serum enzyme elevations and has been linked to cases of acute liver injury, including acute cholestatic hepatitis and venous-occlusive...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Definition

Ifosfamide is a parenterally administered alkylating agent similar to cyclophosphamide that is used in the treatment of several forms of cancer including lymphomas, , and advanced forms of solid organ cancer such as breast, testicular, ovarian, gastric, and lung cancer. Ifosfamide therapy is associated with minor transient serum enzyme elevations and has been linked to cases of injury, including acute cholestatic and venous-occlusive disease. Ifosfamide is a chemotherapeutic agent chemically related to nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Ifosfamide is a synthetic analog of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication. This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04)

Ifosfamide is the simplest member of the class of ifosfamide’s that is 1,3,2-oxazaphosphinan-2-amine 2-oxide substituted by 2-chloroethyl groups on both the nitrogen atoms respectively. It is a nitrogen mustard alkylating agent used in the treatment of advanced breast cancer. It has a role as an antineoplastic agent, an immunosuppressive agent, an alkylating agent, an environmental contaminant, and a xenobiotic.

Mechanism of Action

The exact mechanism of ifosfamide has not been determined but appears to be similar to other alkylating agents. Ifosfamide requires biotransformation in the liver by mixed-function oxidases (cytochrome P450 system) before it becomes active. After metabolic activation, active metabolites of ifosfamide alkylate bind with many intracellular molecular structures, including nucleic acids. The cytotoxic action is primarily through the alkylation of DNA, done by attaching the N-7 position of guanine to its reactive electrophilic groups. The formation of inter and intra-strand cross-links in the DNA results in cell death. Mechanism of action: metabolites cause the alkylation of DNA.

Ifosfamide, a structural analog of cyclophosphamide, belongs to the oxazaphosphorine class of antitumor alkylating agents which must be activated by the mixed-function oxidase system of the liver. The 4-hydroxy oxazaphosphorines are a reactive species capable of interacting with nucleic acids & cellular materials to cause cell damage & death. The 4-hydroxy metabolite spontaneously liberates acrolein in many sites throughout the body & it is this substance that is responsible for oxazaphosphorine urotoxicity. Both ifosfamide & cyclophosphamide produce characterized by tissue & ulceration followed by sloughing of mucosal epithelial cells, necrosis of smooth muscle fibers & , & culminating in focal hemorrhage. The selective urotoxicity of oxazaphosphorine occurs because the contains a very low content of thiol cmpds (glutathione, cysteine) which, by virtue of their nucleophilic sulfhydryl groups, are able to react & neutralize many reactive chemicals. Because the metabolic activation of ifosfamide proceeds more slowly than that of cyclophosphamide, doses of ifosfamide are 3-4 times higher than those of cyclophosphamide. This explains the higher incidence of urotoxicity associated with ifosfamide.

Ifosfamide requires activation by microsomal liver enzymes to active metabolites in order to exert its cytotoxic effects. Activation occurs by hydroxylation at the ring carbon atom 4 to form the unstable intermediate 4-hydroxyifosfamide. This metabolite then rapidly degrades to the stable urinary metabolite 4-ketoifosfamide. The stable urinary metabolite, 4-carboxyifosfamide, is formed upon the opening of the ring. These urinary metabolites have not been found to be cytotoxic. N, N-bis (2-chloroethyl)-phosphoric acid diamide (phosphoramide) and acrolein are also found. The major urinary metabolites, dechloroethyl ifosfamide, and dechloroethyl cyclophosphamide are formed upon enzymatic oxidation of the chloroethyl side chains and subsequent dealkylation. It is the alkylated metabolites of ifosfamide that have been shown to interact with DNA. Ifosfamide is cycle-phase nonspecific.

Indications

  • Used as a component of various chemotherapeutic regimens as third-line therapy for or germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cancer, as well as in conjunction with surgery and/or in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin’s .
  • Ifosfamide is a parenterally administered alkylating agent similar to cyclophosphamide that is used in the treatment of several forms of cancer including lymphomas, sarcoma and advanced forms of solid organ cancer such as breast, testicular, ovarian, gastric and lung cancer.
  • Ifosfamide is an alkylating and immunosuppressive agent used in for the treatment of cancers, including testicular cancer, ovarian cancer, cervical cancer, osteosarcoma, bladder cancer, small cell lung cancer, and non-Hodgkin’s lymphoma.
  • Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin’s lymphoma.
  • Bladder Cancer, Cancer
  • Cervical Cancer
  • Ewing’s Sarcoma
  • Head and Neck
  • Lymphoma, Hodgkins
  • of
  • Non-Hodgkin’s Lymphoma (NHL)
  • Osteosarcoma
  • Ovarian Cancer
  • Small Cell Lung Cancer (SCLC)
  • Soft Tissue Sarcoma
  • Testicular Germ Cell Cancer
  • Advanced thymic carcinoma

Use in Cancer.gov

Ifosfamide is approved to be used with other drugs to treat:

Ifosfamide is also being studied in the treatment of other types of cancer.

Uses

  • Ifosfamide currently is approved for use in combination with other drugs for germ-cell testicular cancer & is widely used to treat pediatric & adult sarcomas. trials also have shown ifosfamide to be active against carcinomas of the & lung & against lymphomas. It is a common component of high-dose chemotherapy regimens with or stem cell rescue; in these regimens, in total doses of 12-14 g/sq m, it may cause neurological toxicity, including coma & death. This toxicity is thought to result from a metabolite, chloracetaldehyde. In addition to hemorrhagic cystitis, ifosfamide causes , , anorexia, , nephrotoxicity, & CNS disturbances (especially somnolence & ).
  • Ifosfamide is indicated, in combination with other antineoplastic agents and a prophylactic agent against hemorrhagic cystitis (such as mesna), for the treatment of germ cell testicular tumors.
  • Ifosfamide is indicated as reasonable medical therapy for the treatment of head and neck carcinoma.
  • Ifosfamide is used for the treatment of soft-tissue sarcomas, Ewing’s sarcoma, and Hodgkin’s and non-Hodgkin’s lymphomas.
  • Ifosfamide is indicated for the treatment of breast carcinomas, cervical carcinoma, small cell lung carcinoma, non-small cell lung carcinoma, ovarian epithelial carcinoma, acute lymphocytic , neuroblastoma, and osteosarcoma.
  • Ifosfamide, in combination therapy, is considered reasonable medical therapy at some point in the management of germ-cell ovarian tumors. (Evidence rating: IIID).
  • Ifosfamide, alone and in combination with other chemotherapeutic agents, is considered reasonable medical therapy at some point in the management of bladder carcinoma (Evidence rating: IIID) and endometrial carcinoma (Evidence rating IIIA).
  • Ifosfamide is indicated, alone or in combination with other chemotherapeutic agents, as second-line therapy for the treatment of Wilms’ tumor in patients who have not responded to or whose disease has progressed during previous treatment (Evidence rating: IIID).

FDA Approved Indications

Ifosfamide is an alkylating agent and an analog of cyclophosphamide, used as a single agent or in combination with other agents to treat a wide variety of malignancies. These malignancies include:

  • Germline tumor of the testis
  • Soft tissue sarcomas
  • Ewing sarcoma
  • Cervical cancer, either recurrent or metastatic
  • Advanced bladder carcinoma
  • Non-Hodgkin lymphoma
  • Hodgkin lymphoma
  • Small and nonsmall cell lung carcinoma
  • Osteosarcoma
  • Ovarian cancer
  • Thymic cancer

Among all these cancers, the Food and Drug Administration (FDA) has approved the drug only for germline tumors of the testis. The indications for the use of ifosfamide include: 

  • Germline Tumor of the Testis – The FDA-approved regimen is ifosfamide and mesna at a 1.2 g/m²/day dose for five days, repeated every three weeks or following count recovery. When using ifosfamide and other chemotherapeutic drugs, mainly cisplatin, paclitaxel, or etoposide, there has been complete remission in about 21 to 26% of the treated population. Aggressive hydration (at least 2 liters oral or IV) is necessary during administration.
  • Soft Tissue Sarcomas (off-label use) – Noncomparative studies have shown that combination therapy with ifosfamide/mesna has demonstrated objective response rates of around 40% when used as induction therapy.
  • Ewing Sarcoma (off-label use) – Doses of ifosfamide vary based on the age group. Used alongside vincristine, etoposide, doxorubicin along with mesna in different regimens. Overall, survival is better with combination therapies. 
  • Cervical Cancer, Recurrent, or Metastatic (off-label use) – Ifosfamide is dosed along with mesna at 1500 g/m2/day every three weeks. When used along with paclitaxel and cisplatin, the response rate was 18 to 45%.
  • Bladder Carcinoma: Mainly Advanced Carcinoma (off-label use) 
  • Non-Hodgkin Lymphoma (off-label use) – Used in Burkitt lymphoma and diffuse large B cell lymphoma (DLBCL) as salvage therapy.
  • Hodgkin Lymphoma (off-label use) Used in relapsed or refractory cases in the RICE regimen (rituximab, ifosfamide, carboplatin, and etoposide) along with mesna.
  • Small and Non-small-cell cancer: When used as maintenance or consolidation has been shown to have more benefits than standard regimens.
  • Osteosarcoma (off-label use)
  • Ovarian Cancer – Used in advanced stages that are platinum-resistant. Many additional trials are underway. Response rates have been more than 40% when used as a combination.
  • Thymic Cancer – Used in advanced stages of thymic cancer. 

Contraindications

  • There are very few known contraindications for the use of ifosfamide. The absolute contraindications are known hypersensitivity to the drug or its components and urinary tract outflow obstruction. Relative contraindications include myelosuppression and severe renal or hepatic impairment.
  • Known hypersensitivity to the drug and/or its components – can result in anaphylaxis with drug administration.
  • Urinary outflow obstruction – there is a high chance of developing cystitis when there is urinary tract obstruction due to an accumulation of toxic compounds.
  • Severe thrombocytopenia and leukopenia – due to the known toxic effect of hematologically, the drug is avoided in severe thrombocytopenia and leukopenia.
  • Severe renal or hepatic impairment – drug metabolism occurs in the liver, and the drug is excreted by the kidneys, prohibiting its use in severe renal and hepatic impairment.
  • cancer metastasis to bone
  • dehydration
  • low amount of potassium in the blood
  • Fanconi syndrome is a condition of the kidneys resulting in excessive urination, thirst, and vomiting
  • anemia
  • decreased blood platelets
  • low levels of white blood cells
  • confusion
  • generalized disorder of peripheral nerves
  • liver problems
  • renal tubular acidosis
  • decreased kidney function
  • inflammation and bleeding of the bladder due to chemotherapy
  • coma
  • the high amount of bilirubin in the blood
  • abnormal liver function tests
  • impaired wound healing
  • pregnancy
  • a patient who is producing milk and breastfeeding
  • the operation to remove kidney tissue

Dosage

Strengths: 1 g; 3 g; 50 mg/mL

Testicular Cancer

  • 1.2 g/m2 IV over at least 30 minutes daily for 5 consecutive days; repeat every 3 weeks or after recovery from hematologic toxicity
  • To prevent bladder toxicity, this drug should be given with extensive hydration (at least 2 liters of oral or IV fluid daily). Mesna should be used to reduce hemorrhagic cystitis.
  • For germ-cell testicular cancer, the dosing regimen is 1.2 g/m²/day IV for the initial five days of a 21-day cycle. IV infusion is typically for a period of 30 minutes along with IV hydration and mesna to prevent bladder toxicity. Ifosfamide is emetogenic; hence, antiemetics are routinely prescribed to prevent chemotherapy-induced nausea and vomiting. Precipitation of ifosfamide-induced encephalopathy (IIE) by aprepitant has been reported in the literature. 

Side Effects

The Most Common

  • nausea
  • vomiting
  • loss of appetite
  • diarrhea
  • sores in the mouth and throat
  • hair loss
  • the general feeling of pain and tiredness
  • swelling, redness, and pain in the place where the medication was injected
  • rash
  • fever, chills, flu symptoms;
  • mouth and throat ulcers;
  • skin sores, pale skin, cold hands, and feet;
  • easy bruising, unusual bleeding
  • rapid heart rate, shallow breathing; or
  • little or no urination, painful or difficult urination, blood in your urine;
  • loss of bladder control; feeling light-headed or short of breath.
  • confusion, unusual thoughts or behavior, hallucinations, seizure (convulsions);
  • itching
  • difficulty breathing or swallowing
  • shortness of breath
  • wheezing
  • irregular heartbeat
  • chest pain
  • hoarseness
  • yellowing of the skin or eyes

More common

  • Agitation
  • black, tarry stools
  • blood in the urine
  • chest pain
  • confusion
  • cough or hoarseness
  • fever or chills
  • Diarrhea
  • hair loss or thinning of the hair
  • swelling or inflammation of the mouth
  • Redness, swelling, or pain at place of injection
  • weight loss
  • frequent urination
  • hallucinations (seeing, hearing, or feeling things that are not there)
  • lower back or side pain
  • painful or difficult urination
  • pale skin
  • shortness of breath
  • sore throat
  • sores, ulcers, or white spots on the lips or in the mouth
  • swollen glands
  • troubled breathing with exertion
  • unusual bleeding or bruising
  • unusual tiredness or weakness

Rare

  • Abdominal or stomach pain or tenderness
  • bleeding gums
  • bluish color
  • changes in skin color
  • clay colored stools
  • dark urine
  • decreased appetite
  • dizziness
  • headache
  • itching
  • loss of appetite
  • nausea and vomiting
  • pain
  • pinpoint red spots on the skin
  • skin rash
  • swelling of the feet or lower legs
  • yellow eyes or skin
  • Blurred vision
  • burning, numbness, tingling, or painful sensations
  • confusion
  • convulsions (seizures)
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • fast or irregular heartbeat
  • sweating
  • troubled breathing
  • unsteadiness or awkwardness
  • weakness in the arms, hands, legs, or feet

Drug Interactions

Pregnancy and Lactation

AU TGA pregnancy category: D
US FDA pregnancy category: Not assigned.

Pregnancy

This drug can cause fetal harm when administered to a pregnant woman. Fetal growth retardation and neonatal anemia have been reported. Adequate methods of contraception should be encouraged. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Women should not become pregnant during therapy. Men should not father a child during therapy and for up to 6 months after. Animal studies have revealed evidence of embryotoxicity, gene mutations, and chromosomal damage. There are no controlled data on human pregnancy.

Lactation

  • Use is contraindicated.
  • Excreted into human milk: Yes
  • This drug is tumorigenic and can harm a nursing infant.

How should this medicine be used?

Ifosfamide comes as a powder to be mixed with liquid to be injected over at least 30 minutes intravenously (into a vein) by a doctor or nurse in a medical facility. It may be injected once a day for 5 days in a row. This treatment may be repeated every 3 weeks. The length of treatment depends on how well your body responds to treatment with ifosfamide.

Your doctor may need to delay your treatment if you experience certain side effects. It is important for you to tell your doctor how you are feeling during your treatment with ifosfamide.

Ifosfamide is also sometimes used to treat bladder cancer, lung cancer, cancer of the ovaries (cancer that begins in the female reproductive organs where eggs are formed), cancer of the cervix, and certain types of soft tissue or bone sarcomas (cancer that forms in muscles and bones). Talk to your doctor about the risks of using this medication for your condition.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before receiving ifosfamide,

  • tell your doctor and pharmacist if you are allergic to ifosfamide, cyclophosphamide (Cytoxan), any other medications, or any of the ingredients in the ifosfamide injection. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins and nutritional supplements you are receiving or plan to take. Be sure to mention the medication listed in the IMPORTANT WARNING section and any of the following: aprepitant (Emend); certain antifungals such as fluconazole (Diflucan), itraconazole (Sporanox), and ketoconazole (Nizoral); certain seizure medications such as carbamazepine (Tegretol), phenobarbital (Luminal), and phenytoin (Dilantin); medications for allergies or hay fever; medications for nausea; opioid (narcotic) medications for pain; rifampin (Rifadin, Rimactane); sedatives; sleeping pills; or sorafenib (Nexavar). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Other medications may also interact with ifosfamide, so be sure to tell your doctor about all the medications you are receiving, even those that do not appear on this list.
  • tell your doctor what herbal products you are receiving, especially St. John’s wort.
  • tell your doctor if you have previously received treatment with other chemotherapy medications or if you have previously received radiation therapy. Also tell your doctor if you have or have ever had heart, kidney, or liver disease.
  • you should know that ifosfamide may slow the healing of wounds.
  • you should know that ifosfamide may interfere with the normal menstrual cycle (period) in women and may stop sperm production in men. Ifosfamide may cause permanent infertility (difficulty becoming pregnant); however, you should not assume that you cannot get pregnant or that you cannot get someone else pregnant. Women who are pregnant or breastfeeding should tell their doctors before they begin receiving this drug. You should not become pregnant or breast-feed while you are receiving ifosfamide. Use a reliable method of birth control to prevent pregnancy while you are receiving ifosfamide and for 6 months after treatments. If you are male, you and your female partner should continue to use birth control for 6 months after you stop receiving ifosfamide injections. If you become pregnant while receiving ifosfamide, call your doctor immediately. Ifosfamide may harm the fetus.

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019763s016lbl.pdf
  2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf
  3. https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1024/
  4. https://www.ebi.ac.uk/chembl/g/#browse/targets
  5. http://ctdbase.org/about/legal.jsp
  6. https://ctdbase.org/detail.go?type=chem&acc=D007069
  7. https://pubchem.ncbi.nlm.nih.gov/compound/Ifosfamide
  8. https://www.bindingdb.org/rwd/bind/info.jsp
  9. https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=189358
  10. https://www.drugs.com/mtm/ifosfamide.html
  11. https://go.drugbank.com/drugs/DB01181
  12. https://www.ncbi.nlm.nih.gov/books/NBK542169/
  13. https://en.wikipedia.org/wiki/Ifosfamide
  14. https://medlineplus.gov/druginfo/meds/a695023.html
  15. https://www.mayoclinic.org/drugs-supplements/ifosfamide-intravenous-route/side-effects/drg-20064266
  16. https://www.webmd.com/drugs/2/drug-2550/ifosfamide-mesna-intravenous/details/list-contraindications
  17. http://www.dgidb.org/downloads
  18. https://www.dgidb.org/drugs/IFOSFAM
  19. https://www.drugbank.ca/legal/terms_of_use
    Ifosfamide
    https://www.drugbank.ca/drugs/DB01181
  20. Therapeutic Target Database (TTD)
    Ifosfamide
    http://idrblab.net/ttd/data/drug/details/D02TLO
  21. https://creativecommons.org/licenses/by-nc/4.0/
    Ifosfamide
    https://commonchemistry.cas.org/detail?cas_rn=3778-73-2
  22. https://www.nlm.nih.gov/copyright.html
    https://chem.nlm.nih.gov/chemidplus/sid/0003778732
    ChemIDplus Chemical Information Classification
    https://chem.nlm.nih.gov/chemidplus/
  23. https://www.cancer.gov/policies/copyright-reuse
    ifosfamide
    https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=759154
    ifosfamide
    https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=109724
  24. EPA DSSTox
    LICENSE
    https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources
    Ifosfamide
    https://comptox.epa.gov/dashboard/DTXSID7020760
    CompTox Chemicals Dashboard Chemical Lists
    https://comptox.epa.gov/dashboard/chemical-lists/
  25. https://echa.europa.eu/web/guest/legal-notice
    Ifosfamide
    https://echa.europa.eu/substance-information/-/substanceinfo/100.021.126
    Ifosfamide
    https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/44783
  26. https://www.fda.gov/about-fda/about-website/website-policies#linking
    IFOSFAMIDE
    https://gsrs.ncats.nih.gov/ginas/app/beta/substances/UM20QQM95Y
  27. Hazardous Substances Data Bank (HSDB)
    IFOSFAMIDE
    https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7023
  28. http://www.hmdb.ca/citing
    Ifosfamide
    http://www.hmdb.ca/metabolites/HMDB0015312
    HMDB0015312_nmr_one_2369
    https://hmdb.ca/metabolites/HMDB0015312#spectra
  29. CCSbase
    IFOSFAMIDE
    CCSbase Classification
    https://ccsbase.net/
  30. ChEBI
    Ifosfamide
    http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5864
    ChEBI Ontology
    http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
  31. https://www.fda.gov/about-fda/about-website/website-policies#linking
    IFOSFAMIDE
    https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm
    FDA Pharmacological Classification
    https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
  32. LiverTox
    LICENSE
    https://www.nlm.nih.gov/copyright.html
    Ifosfamide
    https://www.ncbi.nlm.nih.gov/books/n/livertox/Ifosfamide/
  33. https://www.cancer.gov/policies/copyright-reuse
    https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C564
    NCI Thesaurus Tree
    https://ncit.nci.nih.gov
  34. https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
    https://clinicaltrials.gov/
  35. DailyMed
    LICENSE
    https://www.nlm.nih.gov/copyright.html
    IFOSFAMIDE
    https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=IFOSFAMIDE
  36. https://www.fda.gov/about-fda/about-website/website-policies#linking
    ifosfamide
    https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset
  37. https://creativecommons.org/licenses/by/4.0/
    https://www.norman-network.com/nds/SLE/
  38. EU Clinical Trials Register
    https://www.clinicaltrialsregister.eu/
  39. https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
  40. https://www.fda.gov/about-fda/about-website/website-policies#linking
    IFOSFAMIDE
    https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
  41. SpectraBase
    https://spectrabase.com/spectrum/Gk83nInlZ98
    IFOSFAMIDE;IF
    https://spectrabase.com/spectrum/69aftUJTO2m
    ISOPHOSPHAMIDE
    https://spectrabase.com/spectrum/B0h8H6H2x7g
    IPHOSPHAMIDE
    https://spectrabase.com/spectrum/3rV6gXAylmu
    IFOSFAMIDE;IF
    https://spectrabase.com/spectrum/3KgN0TyR3xD
  42. NIST Mass Spectrometry Data Center
    LICENSE
    https://www.nist.gov/srd/public-law
    Ifosfamide
    http://www.nist.gov/srd/nist1a.cfm
  43. https://publications.iarc.fr/Terms-Of-Use
    Isophosphamide
    https://monographs.iarc.who.int/list-of-classifications
    IARC Classification
    https://www.iarc.fr/
  44. MassBank Europe
    LICENSE
    https://github.com/MassBank/MassBank-web/blob/main/MassBank-Project/LICENSE.txt
    https://massbank.eu/MassBank/Result.jsp?inchikey=HOMGKSMUEGBAAB-UHFFFAOYSA-N
  45. https://mona.fiehnlab.ucdavis.edu/documentation/license
    Ifosfamide
    https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=compound.metaData%3Dq%3D%27name%3D%3D%22InChIKey%22%20and%20value%3D%3D%22HOMGKSMUEGBAAB-UHFFFAOYSA-N%22%27
  46. NCI Cancer Drugs
    LICENSE
    https://www.cancer.gov/policies/copyright-reuse
    Ifex (Ifosfamide)
    https://www.cancer.gov/about-cancer/treatment/drugs/ifosfamide
  47. NIPH Clinical Trials Search of Japan
    https://rctportal.niph.go.jp/en/
  48. https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
    ifosfamide
    https://rxnav.nlm.nih.gov/id/rxnorm/5657
  49. https://www.whocc.no/copyright_disclaimer/
    https://www.whocc.no/atc/
    ATC Code
    https://www.whocc.no/atc_ddd_index/
  50. PubChem
    https://pubchem.ncbi.nlm.nih.gov
  51. Springer Nature
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=14054574-640483507
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=14054574-640500896
  52. https://creativecommons.org/licenses/by-nc-nd/4.0/
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=14054574-640485104
  53. https://www.who.int/about/who-we-are/publishing-policies/copyright
    Ifosfamide
    https://list.essentialmeds.org/medicines/94
  54. https://creativecommons.org/publicdomain/zero/1.0/
    Ifosfamide
    https://www.wikidata.org/wiki/Q418560
  55. Wiley
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=wiley&sourceid=119401
  56. https://www.nlm.nih.gov/copyright.html
    Ifosfamide
    https://www.ncbi.nlm.nih.gov/mesh/68007069
    MeSH Tree
    http://www.nlm.nih.gov/mesh/meshhome.html
    Antineoplastic Agents, Alkylating
    https://www.ncbi.nlm.nih.gov/mesh/68018906
  57. https://www.kegg.jp/kegg/legal.html
    Therapeutic category of drugs in Japan
    http://www.genome.jp/kegg-bin/get_htext?br08301.keg
    Anatomical Therapeutic Chemical (ATC) classification
    http://www.genome.jp/kegg-bin/get_htext?br08303.keg
    Drug Groups
    http://www.genome.jp/kegg-bin/get_htext?br08330.keg
  58. UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)
    GHS Classification Tree
    http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
  59. EPA Substance Registry Services
    LICENSE
    https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources
    EPA SRS List Classification
    https://sor.epa.gov/sor_internet/registry/substreg/LandingPage.do
  60. PATENTSCOPE (WIPO)
    SID 388353803
    https://pubchem.ncbi.nlm.nih.gov/substance/388353803
  61. NCBI
    https://www.ncbi.nlm.nih.gov/projects/linkout

RX Medical Knowledge Graph

Explore this medical topic

Continue through verified related conditions, investigations, medicines, and patient guides. These links are educational and do not replace professional medical advice.

Related medical topics

COVID‑19 Vaccine - Uses, Dosage, Side Effects, Interactions83% relationship confidence Dosage of Filgrastim - Side Effects, Interaction83% relationship confidence Estrogen Drug - Uses, Dosage, Side Effects, Interaction83% relationship confidence Filgrastim - Uses, Dosage, Side Effects, Interaction83% relationship confidence Influenza Vaccines - Uses, Dosage, Side Effect, Interaction83% relationship confidence Lipegfilgrastim - Uses, Dosage, Side Effects, Interaction83% relationship confidence Meropenem - Uses, Dosage, Side Effects, Interactions83% relationship confidence What Is Antacids? -Uses, Dosage, Side Effects, Interaction83% relationship confidence
More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia?, Pain? Associated With Fibromyalgia?, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)
RX Clinical Pathway Engine

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library
  1. Understand the condition Begin with the essential facts and a clear explanation of the topic.
  2. Recognize symptoms Learn common symptoms, signs, and patterns of presentation.
  3. Know when to seek help Review urgent warning signs and when professional assessment may be needed.
  4. Understand causes and risks Explore causes, risk factors, mechanisms, and contributing conditions.
  5. Explore tests and diagnosis Learn how clinicians assess the condition and which investigations may be discussed.
  6. Learn treatment approaches Review general treatment categories and management principles.
  7. Understand medicines safely Continue to medicine education, uses, precautions, and monitoring.
  8. Plan monitoring and follow-up Understand monitoring, complications, rehabilitation, and follow-up learning.
  9. Review prevention and self-care Explore prevention, healthy routines, and questions to discuss with a clinician.

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Ifosfamide – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.